Agreement - March 17, 2025
AstraZeneca enters licensing agreement with Alteogen
The two companies have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology.
Acquisition - March 17, 2025
AstraZeneca to acquire EsoBiotec
EsoBiotec is a biotechnology company focusing on in vivo cell therapies that has demonstrated promising early clinical activity.
Pharma Business - March 12, 2025
PharmNovo receives positiv FDA feedback
The company has received positive and constructive feedback for its lead drug product PN6047, a selective delta opioid receptor agonist, from the U.S. Food and Drug Administration (FDA).
Business article - March 12, 2025
Boule Diagnostics closes BM950 project and announces new portfolio strategy
Boule Diagnostics announces the decision to close the BM950 project due to newly identified technical issues that have significantly impacted the project’s time to market and overall profitability.
Agreement - March 7, 2025
Kancera signs letter of intent agreement with Recardio
The company has signed a letter of intent agreement with the private US biotech company, Recardio with the objective of combining both companies’ assets and forming a late clinical-stage multi-product cardiovascular-focused specialty care company.
Pharma Business - March 4, 2025
AstraZeneca’s Enhertu recommended for approval in the EU by CHMP
AstraZeneca and Daiichi Sankyo’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.
